LAUSR

656 www.ccmjournal.org April 2018 • Volume 46 • Number 4 16. U.S. Food and Drug Administration: Guidance for Industry PatientReported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Rockville, MD, U.S. Department of Health and Human Services, 2009 17. Levin M, Quint PA, Goldstein B, et al: Recombinant bactericidal/ permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: A randomised trial. rBPI21 meningococcal sepsis study Group. Lancet 2000; 356: 961–967 18. Nadel S, Goldstein B, Williams MD, et al; REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspective (RESOLVE) study group: Drotrecogin alfa (activated) in children with severe sepsis: A multicentre phase III randomised controlled trial. Lancet 2007; 369:836–843 19. Moler FW, Silverstein FS, Holubkov R, et al; THAPCA Trial Investigators: Therapeutic hypothermia after in-hospital cardiac arrest in children. N Engl J Med 2017; 376:318–329 20. Moler FW, Silverstein FS, Holubkov R, et al; THAPCA Trial Investigators: Therapeutic hypothermia after out-of-hospital cardiac arrest in children. N Engl J Med 2015; 372:1898–1908 21. Agus MS, Wypij D, Hirshberg EL, et al; HALF-PINT Study Investigators and the PALISI Network: Tight glycemic control in critically ill children. N Engl J Med 2017; 376:729–741 22. Granja C, Póvoa P, Lobo C, et al: The predisposition, infection, response and organ failure (Piro) sepsis classification system: Results of hospital mortality using a novel concept and methodological approach. PLoS One 2013; 8:e53885 23. Willson DF, Thomas NJ, Markovitz BP, et al; Pediatric Acute Lung Injury and Sepsis Investigators: Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: A randomized controlled trial. JAMA 2005; 293:470–476 24. Tejera P, Meyer NJ, Chen F, et al: Distinct and replicable genetic risk factors for acute respiratory distress syndrome of pulmonary or extrapulmonary origin. J Med Genet 2012; 49:671–680 25. Rimpau S, Joffe AR: Interpretation of gene associations with risk of acute respiratory distress syndrome: P values, Bayes factors, positive predictive values, and need for replication. Crit Care 2016; 20:402 26. Odetola FO, Gebremariam A, Davis MM: Comorbid illnesses among critically ill hospitalized children: Impact on hospital resource use and mortality, 1997–2006. Pediatr Crit Care Med 2010; 11:457–463 27. Bone MF, Feinglass JM, Goodman DM: Risk factors for acquiring functional and cognitive disabilities during admission to a PICU*. Pediatr Crit Care Med 2014; 15:640–648 28. Wong HR, Cvijanovich NZ, Anas N, et al: Pediatric sepsis biomarker risk model-II: Redefining the pediatric sepsis biomarker risk model with septic shock phenotype. Crit Care Med 2016; 44:2010–2017 29. Wong HR, Sweeney TE, Lindsell CJ: Simplification of a septic shock endotyping strategy for clinical application. Am J Respir Crit Care Med 2017; 195:263–265 30. Orwoll BE, Sapru A: Biomarkers in pediatric ARDS: Future directions. Front Pediatr 2016; 4:55 31. Tantaleán JA, León RJ, Santos AA, et al: Multiple organ dysfunction syndrome in children. Pediatr Crit Care Med 2003; 4:181–185 32. Lone NI, Walsh TS: Impact of intensive care unit organ failures on mortality during the five years after a critical illness. Am J Respir Crit Care Med 2012; 186:640–647 33. Ward SL, Turpin A, Spicer AC, et al: Long-term pulmonary function and quality of life in children after acute respiratory distress syndrome: A feasibility investigation. Pediatr Crit Care Med 2017; 18:e48–e55